ReviewCureus2025
The Role of Extracorporeal Membrane Oxygenation in Severe Acute Respiratory Distress Syndrome (ARDS): A Comprehensive Review of Current Evidence and Future Directions.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pathogenesis of MRSA-influenza co-infection: implications for ECMO therapeutic strategies - a mini-review.Frontiers in immunology · 2026Review
- Clinical Outcomes of Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in Patients with Traumatic Brain Injury or Spontaneous Intracerebral and Subarachnoid Hemorrhages: A Retrospective PILOT Study.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by refractory hypoxemia and high mortality, particularly in cases unresponsive to conventional therapies. Extracorporeal membrane oxygenation (ECMO) has emerged as a critical rescue modality, providing temporary support for oxygenation and ventilation while mitigating ventilator-induced lung injury. This comprehensive review evaluates the current role of ECMO in managing severe ARDS, focusing on its indications, patient selection criteria, and the evolution of ECMO technologies. A detailed analysis of pivotal clinical trials and observational studies is presented, highlighting the evidence supporting its efficacy and safety. Key complications associated with ECMO, including bleeding, thrombosis, and infections, are discussed, along with strategies to minimize these risks. Despite advances, the optimal timing of ECMO initiation and the long-term outcomes of patients remain areas of ongoing research. Emerging innovations, such as portable ECMO systems and integration with advanced imaging modalities, have the potential to expand their applicability and improve patient outcomes. Furthermore, this review outlines the implications of recent guideline updates and expert consensus for standardizing ECMO practices globally. By synthesizing current evidence, this study underscores the evolving role of ECMO in ARDS management and identifies future research priorities to refine its use in clinical practice, ultimately aiming to improve survival and quality of life for patients with severe ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.